Free Trial

RD Lewis Holdings Inc. Purchases Shares of 23,968 Pfizer Inc. (NYSE:PFE)

Pfizer logo with Medical background
Remove Ads

RD Lewis Holdings Inc. acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 23,968 shares of the biopharmaceutical company's stock, valued at approximately $617,000.

Other hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after acquiring an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI raised its holdings in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares in the last quarter. Parnassus Investments LLC raised its holdings in Pfizer by 3.7% during the 3rd quarter. Parnassus Investments LLC now owns 4,390,705 shares of the biopharmaceutical company's stock valued at $127,067,000 after buying an additional 156,894 shares during the period. Finally, TrinityPoint Wealth LLC raised its holdings in Pfizer by 85.5% during the 3rd quarter. TrinityPoint Wealth LLC now owns 191,544 shares of the biopharmaceutical company's stock valued at $5,543,000 after buying an additional 88,258 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PFE shares. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday. Finally, Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Check Out Our Latest Research Report on PFE

Pfizer Stock Down 0.4 %

Shares of PFE traded down $0.10 during midday trading on Wednesday, reaching $26.22. 26,709,469 shares of the stock were exchanged, compared to its average volume of 35,765,103. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company's 50 day moving average is $26.21 and its two-hundred day moving average is $27.09. The company has a market capitalization of $148.57 billion, a P/E ratio of 18.60, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. The business's revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

These Are the 3 Stocks Most Likely to SPLIT in 2025

These Are the 3 Stocks Most Likely to SPLIT in 2025

MarketBeat analyst Thomas Hughes breaks down why companies split their stock and reveals his top three picks most likely to split next year.

Related Videos

7 Inflation-Proof Stocks to Protect Your Portfolio
7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads